Safety, Tolerability and Activity Study of Multiple Doses of ISIS-SGLT2Rx in Healthy Volunteers

Inclusion Criteria: * Age 18 to 65 years * Male or female gender although females must be post-menopausal or surgically sterile (hysterectomy, oophorectomy or tubal ligation) * Give written informed consent to participate in the study and availability for all study requirements * Fasting plasma glucose \</= the upper limit of the laboratory's reference range (ULN) * HbA1c \</= ULN * BMI \< 30 kg/m² * Agree to maintain steady hydration throughout study participation and agree not to fluid restrict Exclusion Criteria: * Pregnant women, nursing mothers or women of childbearing potential * Clinically significant abnormalities in medical history or physical examination * Clinically significant abnormalities in laboratory examination (including ALT \> ULN, AST \> ULN, bilirubin \> ULN, creatinine \> ULN, urine protein positive by urine dipstick, platelets \< lower limit of normal and any other clinically significant laboratory findings) * Estimated GFR \< 60 mL/min per 1.73m² * History of clinically significant abnormalities in coagulation parameters * Positive test result for HIV, hepatitis B virus, and/or hepatitis C virus * Active infection requiring antiviral or antimicrobial therapy * Subjects on chronic or acute prescription medication may be permitted after discussion with the Isis Medical Monitor * Malignancy (with the exception of basal or squamous cell carcinoma of the skin if adequately treated and no recurrence for \> 1 year) * Any other concurrent condition which, in the opinion of the Investigator, would preclude participation in this study or interfere with compliance * Past and present history of alcohol or drug abuse (defined as \> 3 units daily) * Undergoing or have undergone treatment with another investigational drug, biologic agent or device within 90 days prior to Screening * Blood donation within three months of Screening